Avery Therapeutics, Inc
Tucson, AZ · Founded 2015 · CIK 0001708135 · Biotech · Private
Tissue engineered cardiac muscle therapeutics for heart failure treatment
averythera.com →- Grants
- $1.1M
- 3 awards
- Sector median: 1
- Raised
- $9.0M
- 2 Form D · Sep 2026
- 1 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 12
- 1 granted · 11 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201620182020202220242026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · HLS16-07: Manufacturing Tissue Engineered Patch to Treat Heart Failure | $483,960 | |
| Private capital raised | Form D · SEC | $500,000 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Development and Assessment of an Engineered Cardiac Tissue for Treating Dilated Cardiomyopathy | $299,998 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Development and Assessment of an Engineered Cardiac Tissue for Treating Dilated Cardiomyopathy | $299,998 | |
| Private capital raised | Form D · SEC | $8,468,859 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1533 | Akeso | — | — |
| 1534 | Ctrl Therapeutics | — | — |
| 1535 | Human Immunology Biosciences | — | — |
| 1536 | Avery Therapeutics, Inc | — | $9.0M |
| 1537 | F2G | — | — |
| 1538 | Glyco Expression Technologies (Corporation) | — | — |
| 1539 | Purilogics, LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Steven GoldmanExecutive Officer
- Jennifer KoevaryExecutive Officer
- Jordan LancasterExecutive Officer
Patents
- Three Dimensional Tissue Compositions And Methods Of Useapplication
- Three Dimensional Tissue Compositions And Methods Of Usegranted
- Compositions And Methods For Cryopreservation And Reconstitution Of Engineered Tissuesapplication
- Cell-free Compositions And Methods For Restoration Or Enhancement Of Tissue Functionapplication
- Cell-free Compositions And Methods For Restoration Or Enhancement Of Tissue Functionapplication
- Compositions And Methods For Cryopreservation And Reconstitution Of Engineered Tissuesapplication
- Therapy For Tissue Regenerationapplication
- Three Dimensional Tissue Compositions And Methods Of Useapplication
- Three Dimensional Tissue Compositions And Methods Of Useapplication
- Viable Cultured Cardiac Matrixapplication
- Mycardia: A Viable Cultured Cardiac Matrixapplication
- Compositions And Methods For Cryopreservation And Reconstitution Of Engineered Tissuesapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.